DengyueMed Report: China's National Medical Products Administration has approved a milestone antitumor new drug—BaiZeAn (Tislelizumab Injection)—for the treatment of various advanced solid tumors, including non-small cell lung cancer (NSCLC), esophageal squamous cell carcinoma (ESCC), and hepatocellular carcinoma. This breakthrough advancement marks a key step in China's...

The global companion diagnostics (CDx) development market was valued at USD 845.99 million in 2024 and is projected to expand at a compound annual growth rate (CAGR) of 7.6% from 2025 to 2034, driven by the increasing integration of biomarker-driven therapies into oncology and precision medicine pipelines. This growth trajectory reflects rising demand for diagnostic tools that can identify...

This Nivolumab Market report has been prepared by considering several fragments of the present Nivolumab market and the upcoming market scenario. The market insights gained through this market research analysis report facilitate a clearer understanding of the market landscape, issues that may interrupt in the future, and ways to position a brand excellently. It consists of...

This Nivolumab market report has been prepared by considering several fragments of the present Nivolumab market and the upcoming market scenario. The market insights gained through this market research analysis report facilitate a clearer understanding of the market landscape, issues that may interrupt in the future, and ways to position a brand excellently. It consists of most-detailed...

Market Overview / Summary The global non-small cell lung cancer market size was valued at USD 34.14 billion in 2024, growing at a CAGR of 14.3% from 2025–2034. Rising global incidence of non-small cell lung cancer (NSCLC), coupled with growing adoption of liquid biopsies and multiplexed platforms is enabling non-invasive monitoring in NSCLC. The adoption of next-generation diagnostics,...